636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
PCOS is a complex condition with significant unmet medical needs, particularly for obese patients struggling with hyperandrogenism and metabolic dysfunction. If Mazdutide proves effective in reducing FAI, it could rep…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
These findings establish hypothalamic Cav3.1 as a crucial neuronal leucine sensor, providing a novel and fundamental understanding of how dietary protein influences satiety and body weight. This discovery suggests tha…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equiv…
If successful, this Phase 2 trial could represent a significant advancement in the treatment of chronic kidney disease, a condition with high morbidity and mortality. A drug that can effectively reduce albuminuria cou…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
The successful outcome of this Phase III trial could represent a monumental step forward in treating MASH, a condition affecting millions globally with no current pharmacological cure. If Survodutide demonstrates sign…
This pilot study represents a novel approach to Type 2 Diabetes Mellitus management, focusing on an intensive, short-term intervention to potentially reverse or significantly improve disease progression. If successful…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
Developing long-acting GLP-1 receptor agonists is paramount for improving patient adherence and convenience in the long-term management of Type 2 Diabetes. If LAPS-Exendin (HM11260C) demonstrates favorable safety and …
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
This study is crucial because it focuses on affordable and accessible interventions for a population disproportionately affected by metabolic and cardiovascular diseases. Identifying effective, well-tolerated, and cos…
This Phase 1 study is a crucial step in the development of a potentially improved oral semaglutide formulation. Understanding the pharmacokinetics of oral semaglutide D under various dosing conditions is essential for…
This large-scale data analysis is crucial for understanding the potential neuroprotective effects of different diabetes medications. If Semaglutide demonstrates a significantly lower risk of dementia/Alzheimer's disea…
This study is crucial for understanding Tirzepatide's performance in patient groups often excluded from or underrepresented in randomized controlled trials. If successful, it could provide valuable evidence supporting…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
This review is crucial because it highlights the escalating global obesity crisis and the urgent need for novel, potentially safer, and more accessible therapeutic options. By systematically exploring natural products…
If successful, this trial could identify a novel dietary supplement, AMPK Charge+®, that effectively improves glycemic control in individuals with prediabetes or Type 2 Diabetes. The potential for AMPK Charge+® to enh…
Successfully managing the gastrointestinal side effects of incretin-based anti-obesity medications is crucial for improving patient compliance and achieving optimal weight loss outcomes. This study's findings could es…
This study is crucial for understanding how lifestyle interventions like endurance exercise can complement pharmacological treatments such as semaglutide in managing Type 2 Diabetes. The key implication is that a comb…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…